Latest News
-
Tuesday - October 19, 2021
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation
Division continues to successfully commercialize its product pipeline in key markets, including XtendFlex soybeans and SmartStax PRO corn in North America, and Intacta 2 Xtend soybeans in South America / Successful launches demonstrate progress towards mid-term growth targets in Crop Science and strength of the division’s innovation, digital transformation and sustainability capabilities » more
-
Tuesday - October 5, 2021
Bayer to invest over €400 million to increase access to modern contraception
Supports Bayer’s global sustainability commitment of providing 100 million women in low- and middle-income countries (LMICs) with access to modern contraception by 2030 / Investment in new production capabilities in Alajuela, Costa Rica and Turku, Finland / Construction of new production site in Costa Rica / Focus on hormonal implants and hormonal intrauterine systems (IUS) / Investment secures long-term supply to meet increased global demand for long-acting reversible contraceptives (LARCs) » more
-
Friday - October 1, 2021
Not intended for U.S. and UK Media – Magnetic Resonance Imaging (MRI) of the Central Nervous System (CNS):
Bayer’s Gadovist™ (Gadobutrol) at a Reduced Dose Demonstrates Non-Inferiority Compared to a Standard Dose of Gadoterate for CNS Imaging
Phase IV LEADER-75 study showed 25 percent reduction in standard dose of gadobutrol is non-inferior to gadoterate full dose in improvement of visualization imaging parameters / Diagnostic equivalence of the two contrast regimens was confirmed by a post hoc analysis » more
-
Monday - September 27, 2021
Not intended for U.S. and UK Media
New data for rivaroxaban in patients following the Fontan procedure and at risk for blood clots and blood clot related events
Pivotal UNIVERSE Phase 3 study published in the Journal of the American Heart Association found rivaroxaban (Xarelto™) was associated with numerically fewer thrombotic events and similar safety compared to aspirin in 2-8 years old children with congenital heart disease who have undergone the Fontan procedure / UNIVERSE data are included in recent New Drug Application to FDA for two new pediatric indications for rivaroxaban » more
-
Sunday - September 26, 2021
Bayer Middle East and UNFPA Egypt highlight the importance of providing accessible family planning and reproductive health services to Egyptian families:
Bayer Middle East announces partnership with the United Nations Population Fund Egypt, to support the Ministry of Health and Population’s ‘Your Right to Plan’ campaign in Egypt on World Contraception Day
The ‘Your Right to Plan’ campaign aims at improving family planning and reproductive health services to Egypt’s underserved communities / The five-year partnership involves a total donation of EUR 330,000 / The program provides access to medical services in relation to family planning, such as OB-GYN examinations, ultrasound diagnosis, and pediatric services » more
-
Wednesday - September 22, 2021
Vividion Therapeutics Announces Formation of Scientific Advisory Board » more
-
Wednesday - September 22, 2021
Bayer to launch organic vegetable seeds portfolio enabling greater access to certified organic market
Initial product offering will focus on key crops for greenhouse and glasshouse markets: tomato, sweet pepper and cucumber / Commercial launch is slated for 2022 in Canada, US, Mexico, Spain and Italy with potential for future expansion » more
-
Monday - September 20, 2021
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
There are limited treatment options available for chronic kidney disease (CKD), and patients often still progress to kidney failure or premature death / The Phase III study FIND-CKD will investigate the effect of finerenone on kidney and cardiovascular outcomes in patients with non-diabetic chronic kidney disease » more
-
Thursday - September 16, 2021
Launch of Bayer Science Collaboration Explorer:
Bayer launches transparency register for scientific collaborations with external partners
Open access database makes new contract-based scientific collaborations with universities, public research institutions and individuals publicly available in Germany » more
-
Thursday - September 16, 2021
Not intended for U.S. and UK Media – ESMO Congress 2021:
Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer
In an updated analysis on the adult subset of non-central nervous system (CNS) / TRK fusion cancer patients from three larotrectinib clinical trials, a high overall response rate (ORR) of 67% with a median duration of response (mDoR) of 49.3 months was observed as well as an extended progression-free survival (PFS; median of 25.8 months) as assessed by investigators / Post hoc sub-analysis of investigator-assessed ORR, DoR and PFS of patients (n=218) show uniformly high ORRs in patients regardless of prior treatment or performance status; highest response rates observed in patients receiving first-line larotrectinib (81%) and being Eastern Cooperative Oncology Group performance status (ECOG PS) 0 (85%) / Safety profile for larotrectinib continues to be consistent with that previously published; analysis on the incidence of fractures in larotrectinib trials shows no fracture related to larotrectinib based on investigator assessment / E-Poster published of a matching-adjusted indirect comparison (MAIC) evaluating efficacy (overall survival [OS], PFS, ORR including complete responses and DoR) and safety observed in clinical trials with larotrectinib compared to entrectinib. MAIC is an alternative method for comparative data when a head-to-head randomized control trial (RCT) is not available and/or possible, like for TRK fusion cancer which is an ultra-rare disease » more
-
Tuesday - September 14, 2021
Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures
Andes has developed novel seed treatment technology that allows crops to thrive without synthetic fertilizers / Funds will aid the development of revolutionary nature-based carbon capture technology » more
-
Thursday - September 9, 2021
SVG Ventures | THRIVE and Bayer Announce their Sustainability Challenge Winners
Winners chosen from a global pool of around 300 applicants from across 57 countries » more
-
Thursday - September 9, 2021
Not intended for U.S. and UK Media
Bayer to highlight expanded research from growing oncology portfolio at ESMO Congress 2021
Updated analyses for Vitrakvi™ (larotrectinib) reaffirm sustained clinical benefits for patients with TRK fusion cancer / Breadth of prostate cancer portfolio on display, including presentations for Nubeqa™ (darolutamide) in non-metastatic castration-resistant prostate cancer (nmCRPC), and Xofigo™ (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) / Oral presentation on analysis from CHRONOS-3 study evaluating Aliqopa™ (copanlisib) plus rituximab in patients with marginal zone lymphoma (MZL) / Ongoing investigator-initiated research featuring StivargaTM (regorafenib) in various indications and difficult-to-treat tumors » more
-
Monday - September 6, 2021
Not intended for U.S. and UK Media
Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
Significant improvement in 24-hour cough counts over placebo after 12 weeks of treatment and with a favorable safety and tolerability profile / Results from PAGANINI Phase IIb dose-finding study presented at the virtual European Respiratory Society (ERS) International Congress 2021 / Currently no treatment approved for refractory chronic cough, a condition affecting one to five percent of people wordwide » more
- ARCHIVIERT
Tuesday - August 31, 2021
Not intended for U.S. and UK Media
Bayer starts Phase III clinical development program OASIS with Elinzanetant
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause » more
-
Saturday - August 28, 2021
Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021
New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression » more
-
Tuesday - August 24, 2021
Not intended for U.S. and UK Media
U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for Xarelto™ plus aspirin
Patients after recent lower-extremity revascularization due to symptomatic PAD now included in the label in the US / Xarelto plus aspirin is the first treatment approach indicated in the US for both coronary artery disease (CAD) and PAD, now including patients post recent lower-extremity revascularization (LER) due to symptomatic PAD » more
-
Thursday - August 19, 2021
Leaps by Bayer Leads USD 45 Million Financing in Sound Agriculture to Accelerate Sustainability Solutions for Food and Agriculture
Sound’s Dual-Technology Platform Uses Biochemistry to Tap into the Natural Capabilities of the Plant to Increase the Speed and Efficiency of Agriculture » more
-
Tuesday - August 17, 2021
Not intended for U.S. and UK Media – ESC Congress 2021 – The Digital Experience:
Bayer to present data from cardiovascular portfolio, including late breaking data from Phase III FIGARO-DKD (finerenone) and various Xarelto™ studies
Detailed results from the FIGARO-DKD study will be presented, which investigated the efficacy and safety of finerenone regarding cardiovascular and kidney outcomes versus placebo in addition to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / Data for finerenone from FIDELITY, a prespecified integrated analysis of FIDELIO-DKD and FIGARO-DKD which together formed the largest Phase III study program to date in CKD and T2D, will be presented / New rivaroxaban (Xarelto™) data from the VOYAGER PAD study in patients with peripheral artery disease and ANTENNA, EMIR and AFIRE studies in patients who have atrial fibrillation / Further data from the Phase III VICTORIA trial provides new insights into use of vericiguat (Verquvo™), including those receiving an angiotensin receptor neprilysin inhibitor (ARNI) / For the first time, worsening heart failure has been explicitly recognized in an update to the European Society of Cardiology (ESC) Guidelines for Acute and Chronic Heart Failure » more
-
Monday - August 16, 2021
Bayer announces filing of petition to U.S. Supreme Court for review of Hardeman decision
Company argues errors on federal preemption and expert evidence standards necessitate review of rulings / Decision could affect thousands of Roundup™ cases and other litigation » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Tuesday, November 9, 2021
Q3 2021 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV